MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...

Armed with positive results in two phase 3 trials, MSD is poised to be the first drugmaker to file for approval of an oral PCSK9 inhibitor for lowering cholesterol. Top-line results from the CORALreef ...

Discover the top 3 undervalued Automobile Components stocks for Friday, December 26 based on AAII’s Stock Grades.

The Parkland Farmers’ Market returns on Sunday, January 4, with Health and Wellness vendors. Held at the Parkland Equestrian ...

MSD's booth is seen during an expo in Shanghai in November. [PHOTO/CHINA DAILY] With a long-term commitment to the Chinese market, United States-based global pharmaceutical company MSD plans to ...